about
Analysis of different HER-2 mutations in breast cancer progression and drug resistancePertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Clinical implications of compounds designed to inhibit ECM-modifying metalloproteinases.Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
P95 HER2 fragments and breast cancer outcome.
@en
type
label
P95 HER2 fragments and breast cancer outcome.
@en
prefLabel
P95 HER2 fragments and breast cancer outcome.
@en
P2093
P2860
P1476
P95 HER2 fragments and breast cancer outcome.
@en
P2093
Deniz Tural
Hasan Mutlu
Saadettin Kilickap
P2860
P304
P356
10.1586/14737140.2014.929946
P577
2014-06-26T00:00:00Z